Retatrutide Glucagon Content: Research Data Analysis
Published: 15 7 月, 2026 17:49
Author: David Rossi
Abstract: Retatrutide, a novel triple agonist (GIP/GLP-1/glucagon), contains a precisely engineered glucagon component ( 30% receptor activation) to maximize energy expenditure. Market data indicates a 47% surge in multi-agonist peptide demand (2024–2030 CAGR). Compared to semaglutide, retatrutide demonstrates superior weight loss (up to 24.2% at 48 weeks) but higher gastrointestinal side effects. Key product parameters include purity ≥99% (HPLC) and endotoxin <0.5 EU/mg. Selecting verified GMP-certified suppliers with third-party COAs is critical for clinical research compliance.